Related Experiment Video

Updated: Oct 10, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K

D154Q Mutation does not Alter KRAS Dimerization

Ingrid Grozavu1, Sarah Stuart2, Anna Lyakisheva1

  • 1Donnelly Centre, University of Toronto, Toronto, ON, Canada; Department of Biochemistry, University of Toronto, Toronto, ON, Canada.

Journal of Molecular Biology
|December 13, 2021
PubMed

Insights

Caution is advised when using the KRAS D154Q mutant to study KRAS dimerization in cancer. This variant forms dimers with wild-type KRAS, indicating it is not dimer-deficient as previously thought.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • KRAS is a frequently mutated oncogene in human cancers.
  • KRAS remains largely undruggable due to incomplete biological understanding.
  • KRAS dimerization is crucial for its signaling function in oncogenesis.

Purpose of the Study:

  • To investigate the dimerization properties of the KRAS D154Q mutant.
  • To determine if the KRAS D154Q mutant can be used to study the role of dimerization in KRAS oncogenicity.
  • To assess the impact of the D154Q mutation on oncogenic KRAS dimerization.

Main Methods:

  • Utilized three distinct protein-protein interaction assays.
  • Analyzed homo- and heterodimerization of KRAS D154Q with wild-type KRAS (KRAS WT).
  • Evaluated the effect of the D154Q mutation on oncogenic KRAS dimerization.

Main Results:

  • The KRAS D154Q mutant demonstrated homo- and heterodimerization with KRAS WT.
  • Oncogenic KRAS dimerization was not impaired by the presence of a secondary D154Q mutation.
  • The D154Q variant is not dimer-deficient as previously suggested.

Conclusions:

  • The KRAS D154Q mutant forms dimers and is not suitable for studying dimer-deficiency.
  • Caution is recommended when using the D154Q variant to investigate the role of dimerization in KRAS oncogenic behavior.
  • Further research is needed to understand KRAS biology and develop effective KRAS-targeted therapies.
Keywords:
Cancer therapeuticsKRASMaMTHOncogenic signallingSIMPLco-immunoprecipitationdimerization

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.8K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.3K
Mutations01:39

Mutations

Overview
85.4K